Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase
- PMID: 10347144
- DOI: 10.1074/jbc.274.23.15978
Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase
Abstract
By using the amino acid sequence motif of tumor necrosis factor (TNF), we searched the expressed sequence tag data base and identified a novel full-length cDNA encoding 285 amino acid residues and named it THANK. THANK is a type II transmembrane protein with 15-20% overall amino acid sequence homology to TNF, LT-alpha, FasL, and LIGHT, all members of the TNF family. The mRNA for THANK was expressed at high levels by peripheral blood leukocytes, lymph node, spleen, and thymus and at low levels by small intestine, pancreas, placenta, and lungs. THANK was also prominently expressed in hematopoietic cell lines. The recombinant purified protein expressed in the baculovirus system had an approximate molecular size 20 kDa with amino-terminal sequence of AVQGP. Treatment of human myeloid U937 cells with purified THANK activated nuclear transcription factor-kappaB (NF-kappaB) consisting of p50 and p65. Activation was time- and dose-dependent, beginning with as little as a 1 pM amount of the cytokines and as early as 15 min. Under the same conditions, THANK also activated c-jun NH2-terminal kinase (JNK) in U937 cells. THANK also strongly suppressed the growth of tumor cell lines and activated caspase-3. Although THANK had all the activities and potency of TNF, it did not bind to the TNF receptors. Thus our results indicate that THANK is a novel cytokine that belongs to the TNF family and activates apoptosis, NF-kappaB, and JNK through a distinct receptor.
Similar articles
-
Suppression of tumor necrosis factor-activated nuclear transcription factor-kappaB, activator protein-1, c-Jun N-terminal kinase, and apoptosis by beta-lapachone.Biochem Pharmacol. 1999 Apr 1;57(7):763-74. doi: 10.1016/s0006-2952(98)00354-2. Biochem Pharmacol. 1999. PMID: 10075082
-
Equine herpesvirus-2 E10 gene product, but not its cellular homologue, activates NF-kappaB transcription factor and c-Jun N-terminal kinase.J Biol Chem. 1999 Apr 9;274(15):9962-8. doi: 10.1074/jbc.274.15.9962. J Biol Chem. 1999. PMID: 10187771
-
Overexpression of gamma-glutamylcysteine synthetase suppresses tumor necrosis factor-induced apoptosis and activation of nuclear transcription factor-kappa B and activator protein-1.Oncogene. 1999 Jul 29;18(30):4371-82. doi: 10.1038/sj.onc.1202811. Oncogene. 1999. PMID: 10439045
-
Regulation of proliferation, survival and apoptosis by members of the TNF superfamily.Biochem Pharmacol. 2003 Oct 15;66(8):1403-8. doi: 10.1016/s0006-2952(03)00490-8. Biochem Pharmacol. 2003. PMID: 14555214 Review.
-
Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.Blood. 2012 Jan 19;119(3):651-65. doi: 10.1182/blood-2011-04-325225. Epub 2011 Nov 3. Blood. 2012. PMID: 22053109 Free PMC article. Review.
Cited by
-
The effects of Jieduquyuzishen prescription-treated rat serum on the BAFF/BAFF-R signal pathway.PLoS One. 2015 Feb 17;10(2):e0118462. doi: 10.1371/journal.pone.0118462. eCollection 2015. PLoS One. 2015. PMID: 25689512 Free PMC article.
-
A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys.Am J Pathol. 2006 Feb;168(2):476-89. doi: 10.2353/ajpath.2006.050600. Am J Pathol. 2006. PMID: 16436662 Free PMC article.
-
Mutational analysis of human BLyS in patients with common variable immunodeficiency.J Clin Immunol. 2006 Jul;26(4):396-9. doi: 10.1007/s10875-006-9026-2. Epub 2006 Jun 1. J Clin Immunol. 2006. PMID: 16838132
-
BAFF, a new target for intravenous immunoglobulin in autoimmunity and cancer.J Clin Immunol. 2007 May;27(3):257-65. doi: 10.1007/s10875-007-9082-2. Epub 2007 Mar 29. J Clin Immunol. 2007. PMID: 17393290
-
Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date.Drug Des Devel Ther. 2017 Mar 13;11:747-757. doi: 10.2147/DDDT.S114552. eCollection 2017. Drug Des Devel Ther. 2017. PMID: 28331294 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous